Daiichi Sankyo's new anticoagulant Lixiana should be available on the NHS in England and Wales for the treatment and prevention of recurrent blood clots in the legs and lungs, according to NICE.

Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced that the first patient has been enrolled into the ELIMINATE-AF study. The multinational, randomised phase 3b study will ...

Daiichi Sankyo Company, Limited (hereafter, "Daiichi Sankyo") today announced results from ELIMINATE-AF, a prospective, randomised, open label, blinded endpoint evaluation (PROBE) design study ...

Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is ...

Daiichi Sankyo’s Lixiana has become the fourth novel oral anticoagulant (NOAC) to be granted approval in the EU. The European Commission has given the green light for Lixiana (edoxaban) to be used to ...

A spokesman for Daiichi Sankyo indicated that the daily listed cost of Lixiana is £2.10, although he told pharmaphorum that "costs around the country may vary because of negotiated procurement ...

Commission's approval of LIXIANA, which means physicians and patients may benefit from a new treatment option to effectively manage these debilitating and life-threatening conditions," said Jan van ...

Daiichi Sankyo has been traveling a rocky road with its new-age anticoagulant Lixiana, but the company's load may be getting lighter. The Japanese pharma has tapped Merck to launch the drug in ...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that Swissmedic, the regulatory authority of Switzerland, has granted approval of Lixiana(R) (edoxaban), an oral, once ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, ... In Japan, Lixiana was the top-selling product, which brought in ¥103.2 billion ...

Daiichi Sankyo Company, Limited today announced that it received approval from the Ministry of Health, Labour and Welfare in Japan for LIXIANA® for the prevention of ischemic stroke and systemic ...

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward ...